PolyPeptide Group AG shareholders approved all proposals put forward by the board of directors at an extraordinary general meeting, including the election of a new board and the removal of key transfer restrictions and voting limitations. The decisions are contingent on the settlement of a public tender offer by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd., for all publicly held registered shares of PolyPeptide. The outcome marks a critical step in the anticipated acquisition of the specialized peptide contract development and manufacturing organization (CDMO) and could reshape the competitive landscape in the fast-growing market for peptide-based active pharmaceutical ingredients, particularly those used in metabolic diseases such as GLP-1 therapies.
Shareholders elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang and Joonkyung Seong as members of the board for a term ending at the conclusion of the next annual general meeting. John Chongbo Rim was elected chair of the board, while Cheol Woo Ryu and Seungho Ryu were elected to the Remuneration and Nomination Committee. All elections are subject to and effective as of the settlement of the tender offer. The new board composition, heavily represented by individuals with ties to Samsung Biologics, signals a decisive shift in control and strategy for PolyPeptide. The company, which dates back to 1952 and operates six GMP-certified facilities across Europe, the U.S. and India, serves a rapidly expanding market for peptide-based therapies. The change in leadership is likely to accelerate the integration of PolyPeptide into Samsung Biologics’ broader biopharma operations, potentially enhancing capacity and capabilities in the peptide CDMO space.
In addition, shareholders resolved to remove from PolyPeptide’s articles of association the transfer restrictions (Vinkulierung) and voting limitations (Stimmrechtsbeschränkungen), subject to the satisfaction or waiver of all offer conditions set forth in the offer prospectus of Samsung Peptide AG dated 31 August 2026, except for the condition in section B.7.1(e). This move eliminates key defensive mechanisms that could have impeded the tender offer, effectively smoothing the path for Samsung Biologics to complete its acquisition. The removal of these restrictions is a significant governance change that underscores the board’s support for the transaction and reduces barriers for shareholders to tender their shares. For the broader peptide CDMO industry, the acquisition could intensify competition and consolidate expertise, as Samsung Biologics gains a established player with a strong portfolio and global manufacturing footprint. PolyPeptide’s exposure to GLP-1 and other metabolic disease therapies aligns with Samsung Biologics’ strategic interests in high-growth biologics segments.
The extraordinary general meeting results were announced via NEWMEDIAWIRE, and further details about PolyPeptide’s operations and market position are available on polypeptide.com. The company also provides updates through its LinkedIn page. With the shareholder approvals now secured, the focus shifts to the completion of the tender offer, which, if successful, will see PolyPeptide become part of Samsung Biologics. The implications for patients, customers and investors are substantial, as the deal could influence the supply and development of peptide-based medicines globally.
